Merck (NYSE: MRK) reported an 8% drop in second quarter sales, reflecting the negative impact of COVID-19. However, sales of $10.9 billion and adjusted EPS of $1.37 topped Street’s views. The pharma giant lifted its outlook for fiscal 2020.
MRK stock rose about 3% in the pre-market trading session following its earnings announcement.
Merck narrowed and lifted FY20 revenue guidance to a range of $47.2 billion to $48.7 billion.
The Kenilworth, New Jersey-based firm also narrowed and raised its earnings outlook for FY20. GAAP EPS is now expected to be between $4.58 and $4.73 and non-GAAP EPS is now expected to be between $5.63 and $5.78.
Merck is accelerating two COVID-19 vaccine development efforts and a novel antiviral candidate. “We are conscious of our abiding responsibility to help advance vaccine and antiviral efforts as part of the global response to SARS-CoV-2 and to ensure broad, equitable and affordable global access to any medicines and vaccines we bring forward,” said CEO Kenneth Frazier.
Snap Inc. (NYSE: SNAP) reported second quarter 2021 earnings results today. Revenues increased 116% year-over-year to $982 million. Net loss amounted to $151.6 million, or $0.10 per share, compared to
Microblogging platform Twitter, Inc. (NYSE: TWTR) Thursday reported a profit for the second quarter of fiscal 2021, compared to a loss last year. Both earnings and revenue came in above
Intel Corporation (NASDAQ: INTC) Thursday reported financial results for the second quarter of 2021. The revenue was reported at $19.6 billion compared to $19.7 billion in the previous year's second